Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 238

Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare

Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.

“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”

As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.

With the emergence of such trends including: personalization of medicine on an “n-of-1” basis, adaptive clinical design, globalization of health care training, compassionate use legislative initiatives for experimental therapies, wider acceptance of complementary medical technologies, and the growth of international medical travel, patients and clinicians are more than ever before, exploring the ability to access the therapies of tomorrow, today.

recovering patient

The estimate of the current market size for procedural medical travel, defined by medical travelers who travel across international borders for the purpose of receiving medical care, is in the range of US $40–55 billion.

Additionally, major clinical trial gaps currently exist across all therapeutic segments that are responsible for human suffering and death. Cancer is one prime example. As a leading cause of morbidity and mortality worldwide for many decades, today there are approximately 14 million new cases diagnosed each year, with over 8 million cancer related deaths annually. It is estimated that less than 5% of these patients, take the initiative to participate in any available clinical studies.

“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Dr. Joel Osorio, Chief of Clinical Development RegenerAge SAPI de CV. “The ability to merge cellular and biologic approaches represents the next step in achieving comprehensive regeneration and disease reversion events in a range of chronic diseases responsible for human suffering and death.”

bioquarklogo

About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About RegenerAge SAPI de CV

RegenerAge SAPI de CV is a novel clinical company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.

Portable bioreactor from MIT produces medications, vaccines on-demand

A new method for medicine.

Imagine a cross between one of those multi-color retractable pens and an epi-pen. But instead of colors, the device would have different medications. Now combine this with a tiny, droplet-sized sweatshop full of obedient single-celled organisms genetically engineered to produce those medications, and you’ve got what a team from MIT just published in Nature Communications: A new project, with funding from DARPA, that has demonstrated the ability to synthesize multiple medications on-demand and as-needed using yeast. The discovery could soon revolutionize our ability to deliver medicine after natural disasters or to remote locations.

Let’s stick with the metaphor of an epi-pen. First, the user presses the actuator, which mixes a chemical trigger into a culture of engineered Pichia pastoris cells. Upon exposure to certain chemical triggers, the cells are programmed to produce a protein: in the report, the team used estrogen β-estradiol, which caused the cells to express recombinant human growth hormone (rHGH), and also methanol, which induced the same culture of yeast to make interferon. By controlling the concentration of the chemical trigger and the population of P. pastoris, the team demonstrated that they could make their device produce a dose of either interferon or rHGH on command. To switch between products, they just pushed another button on the microbioreactor, which flushes out the cell culture with clean, sterile fluid.

“…rapid and switchable production of two biologics from a single yeast strain as specified by the operator.” –Lu, Ram et al

Promising Cancer-Fighting Gene Immunotherapy Could Be Used Against HIV, UCLA Research Suggests

AWESOME.

New UCLA research suggests that a gene-based immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS.

In a study to be published in an August issue of the bi-monthly peer-reviewed Journal of Virology, researchers with the UCLA AIDS Institute and Center for AIDS Research found that recently discovered potent antibodies can be used to generate chimeric antigen receptors, or CARs, that can be used to kill cells infected with HIV-1.

CARs are artificially created immune T-cells that have been engineered to produce receptors on their surface that are designed to target and kill specific cells containing viruses or tumor proteins. The use of these chimeric receptors is currently the focus of gene immunotherapy against cancer, but they could also be used to create a strong immune response against HIV, said Dr. Otto Yang, professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA and the study’s corresponding author.

Yale team designs gene modification system

A Yale research team has designed a system to modify multiple genes in the genome simultaneously, while also minimizing unintended effects. The gene-editing “toolbox” provides a user-friendly solution that scientists can apply to research on cancer and other disciplines, according to a news release from Yale.

The study was published on July 26 in Nucleic Acids Research.

The news release states that, with modern genetic engineering techniques, researchers can edit genes in experiments. This allows researchers to study important disease-related genes and may ultimately allow them to treat genetic diseases by making edits in specific sites of the human genome. However, progress has been hampered by several challenges, including the editing of unintended sites — referred to as off-target effects.

U.S. wary on biotech advances; gene editing, CRISPR ‘raising urgency’

Hmmm.

We can rebuild him; we have the technology—but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

A new report, based on a survey of 4,700 U.S. adults coming out of the Pew Research Center, looked at a range of views on certain advances in biology, with opinions split on the ethics and long-term problems associated with enhancing human capacity.

When asked about gene editing, the majority of those surveyed, 68%, said they would be “very” or “somewhat” worried about its implications.

Most people are too scared to use brain chips and synthetic blood to improve performance

On the path towards Singularity — I believe that this is an individual choice. However, to remain relevant and competitive in industry we may see a day when folks will require this type of enhancement to compete, perform in military operations, etc.

The researchers carried out a survey of more than 4,700 US adults.

The survey asked the public on views of gene editing, implantation of brain chips, and transfusions of synthetic blood.

More said they would not want enhancements of their brains and their blood: 66 per cent and 63 per cent, respectively, than said they would want them — 32 per cent and 35 per cent.

Building a Better Human With Science? The Public Says, No Thanks

The public was unenthusiastic on all counts, even about protecting babies from disease.

Americans aren’t very enthusiastic about using science to enhance the human species. Instead, many find it rather creepy.

A new survey by the Pew Research Center shows a profound distrust of scientists, a suspicion about claims of progress and a real discomfort with the idea of meddling with human abilities. The survey also opens a window into the public’s views on what it means to be a human being and what values are important.

Pew asked about three techniques that might emerge in the future but that are not even close to ready now: using gene editing to protect babies from disease, implanting chips in the brain to improve people’s ability to think, and transfusing synthetic blood that would enhance performance by increasing speed, strength and endurance.

Engineered bacteria deliver an anti cancer tumor toxin in mice before self-destructing

I never get tired of hearing more information on this research.

A synthetic genetic circuit programmed into an attenuated Salmonella enterica subspecies can be used to systemically deliver an anti-tumor toxin into mice with cancer. The circuit allows the bacterial cells inside a tumor to synchronously self-destruct by lysis, releasing the toxin directly in the tumor.

Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs.

“This impressive study represents a big step towards one of the great dreams of synthetic biology: rationally programming cells, in this case bacteria, to exhibit complex, dynamic, and beneficial behaviors in a host organism,” Michael Elowitz, whose Caltech lab builds synthetic genetic circuits and who was not involved in the work, wrote in an email to The Scientist.

Chinese team to pioneer first human CRISPR trial

(Medical Xpress)—A team of researchers at Sichuan University’s West China Hospital has announced plans to begin a clinical trial where cells modified using the CRISPR gene editing technique will be used on human beings for the very first time. They plan to edit genes in such a way as to turn off a gene that encodes for a protein that has been shown by prior research to slow an immune response and by so doing treat patients with lung cancer.

The CRISPR has been in the news a lot of late as scientists creep ever closer to using it as a means to treat diseases or to change the very nature of biological beings. China has been a leader in promoting such research on human beings—they were the first to use the technique to on human embryos.

This new effort is seen as far less controversial—a team in the U.S. is planning a similar study as soon as they can get regulators to greenlight their project. The Chinese team plans to retrieve T cells from patients that have incurable and then edit the genes in those cells. More specifically, they will be looking to disable a gene that encodes for a protein called PD-1—prior research has shown that it acts as a brake on an to help prevent attacks on healthy cells. Once the cells have been edited and inspected very carefully to make sure there were no editing errors they will be allowed to multiply and then all of the cells will be injected back into the same patient’s bloodstream. It is hoped that the edited cells will cause the immune system to mount a more aggressive attack on , killing them and curing the patient.

/* */